NBIX Congressional Stock Trades
NEUROCRINE BIOSCIENCE INC
Last disclosed trade Aug 26
Every disclosed trade in NBIX by members of Congress under the STOCK Act, parsed by Coldpine. Informational only, sourced from public filings. Not investment advice.
Sample · the intelligence layer
Michael T. McCaul · Sold $NBIX · Aug 14 · $50K–$100K
Managed-account penalty applied (x 0.20): filings dominated by trust or wealth-manager activity are discounted.
Every disclosed trade in the database gets this treatment: a four-factor score and a written read from Coldpine’s AI-based analysis. Informational only, not investment advice. Create a free account for every scored trade →
Follow $NBIX
Get notified when any member of Congress trades $NBIX. Free, no card, no spam.
The record on $NBIX
Coldpine has parsed 5 disclosed trades in $NBIX by 2 members of Congress, drawn from 3 periodic transaction reports dated Feb 10, 2023 through Aug 26, 2024. All of them came from House members, filed 1 by Democrats and 4 by Republicans.
Of the 5 trades with a known filing lag, every one was reported inside the STOCK Act's 45-day window. The median lag was 21 days. The longest was 31 days: a $NBIX purchase by Michael T. McCaul dated Aug 14, 2023, disclosed Sep 14, 2023. How late filing is measured across all of Congress is in the late-filers study.
5 of the 5 trades that list an account holder (100%) were reported under a spouse, dependent child, or joint account rather than the member directly.
Michael T. McCaul filed the most $NBIX purchases (1), and Michael T. McCaul the most sales (3).
Activity peaked in 2023 with 3 trades.
Members who trade NBIX
Recent disclosed trades in NBIX
| Date | Member | Type | Amount |
|---|---|---|---|
| Aug 26 | Michael T. McCaul(TX) | sell | $1K–$15K |
| Aug 26 | Michael T. McCaul(TX) | sell | $1K–$15K |
| Aug 14 | Michael T. McCaul(TX) | buy | $1K–$15K |
| Aug 14 | Michael T. McCaul(TX) | sell | $50K–$100K |
| Feb 10 | Rohit Khanna(CA) | sell | $1K–$15K |
Data sourced from public STOCK Act disclosures. Coldpine is a publisher of intelligence on congressional disclosures, not an investment adviser. See full history and scores, free with an account →